To address the challenge of CAR-T cell therapy in AML, He and colleagues (30) developed a combinatory bispecific and split CAR (BissCAR) T-cell system that targets CD13 and TIM3. The gene discussed is ANPEP; the disease is acute myeloid leukemia.